

<!-- page 1 -->

I fldgi ( ^I& fPoh - YS% ,xld m%cd;dka;s%l iudcjd§ ckrcfha w;s úfYI .eiÜ m;%h - 2018'08'31
PART I : SEC. (I) - GAZETTE   EXTRA  ORDINARY   OF   THE   DEMOCRATIC   SOCIALIST   REPUBLIC   OF   SRI   LANKA - 31.08.2018
                  
       
              
               
            
        
                  
     
         
             
         
               
            
               
               
            
               
        
                 
        
              
               
            
         
                  
PART I : SECTION (I) — GENERAL  
Government  Notiﬁ cations
This Gazette Extraordinary can be downloaded from www.documents.gov.lk 
1A   PG 4189 — 807  (08/2018)
w;s úfYI
wxl 2086$37 - 2018 wf.daia;= ui 31 jeks isl=rdod - 2018'08'31
No. 2086/37 - FRIDAY ,  AUGUST  31, 2018
EXTRAORDINARY
The Gazette of the Democratic Socialist Republic of Sri Lanka
(Published by Authority)
Y%S ,xld m%cd;dka;%sl iudcjd§ ckrcfha .eiÜ m;%h
L.D.-B 9/2016
NATIONAL MEDICINES REGULATORY AUTHORITY ACT, No. 5 OF 2015
REGULATIONS made by the Minister of Health, Nutrition and Indigenous Medicine under Section 142 of the National 
Medicines Regulatory Authority Act, No.5 of 2015 read with Sections 3 and 118 of the aforesaid Act. 
 Dr. RAJITHA SENARATNE,
 Minister of Health, Nutrition and Indigenous Medicine.
Colombo,
29th August, 2018.
Regulations
The Ceiling on Prices Regulations No.2 of 2016 published in the Gazette Extraordinary No.1989/61 of October 
21, 2016 as amended by regulations published in Gazette Extraordinary No. 2049/ 31 of December 14, 2017 are hereby 
amended as follows: -
(1)  by the repeal of regulation 3 thereof and the substitution therefor of the following:--
“3. The Maximum Retail Price (hereinafter referred to as the “MRP”) limits in respect of the Scheduled 
drugs shall also be applicable to all brand names, generic names, dosage forms and strengths of the Scheduled 
drugs.”

<!-- page 2 -->

2 I fldgi ( ^I& fPoh - YS% ,xld m%cd;dka;s%l iudcjd§ ckrcfha w;s úfYI .eiÜ m;%h - 2018'08'31
PART I : SEC. (I) - GAZETTE   EXTRA  ORDINARY   OF   THE   DEMOCRATIC   SOCIALIST   REPUBLIC   OF   SRI   LANKA - 31.08.2018
(2)  immediately after regulation 5, by the insertion of the following which shall have effect as regulation 5A: -
“5A. A manufacturer, importer, trader, distributor, pharmacist, medical practitioner, medical institution 
including a private medical institution, pharmacy or person who or which is in the possession of a Scheduled 
drugs as speciﬁ ed in Column II of Part II of the Schedule hereto for the purpose of sale of such medicine on 
and after the date on which this regulation comes in to operation shall not be sold above the MRP as speciﬁ ed 
in Column V of the said Schedules.”
(3)  immediately after the renumbered regulation 5A thereof, by the insertion of the following regulation:-
“5B. Where any dosage form or strength of the Scheduled drugs are not speci ﬁ ed in such Schedule, the 
maximum price limit for the dosage form or strength not so speci ﬁ ed shall be the maximum retail price limit 
as shall be ﬁ xed by the National Medicines Regulatory Authority.”.
(4)  by the insertion of the following regulation immediately after regulation 10 thereof: -
“11. For the purpose of these regulations –
“Medical Practitioner” shall have the same meaning as in the Medical Ordinance (Chapter 105);
 “Private medical institution” shall have the same meaning assigned to it by the Private Medical Institutions 
(Registration) Act, No.21 of 2006.
(5)  immediately after the caption “Schedule”, by the insertion of the following:
“Part I” 
(6)  by the insertion of the following Part, immediately after Part I of the Schedule:- 
“Part II” 
SCHEDULE
PART II
MAXIMUM RETAIL PRICES OF THIRTEEN SELECTED MEDICINE
Column I Column II
Generic Name
Column III
Route of Administration/
dosage form
Column IV
Strength
Column V
MRP (SLR)
1 CEFTAZIDIME INJECTION 500mg 480.00
CEFTAZIDIME INJECTION 1g 800.00
2 CEFTRIAXONE INJECTION 250 mg 240.00
CEFTRIAXONE INJECTION 500 mg 450.00
CEFTRIAXONE INJECTION 1 g 700.00
3 CEFOTAXIME INJECTION 500 mg 225.00
CEFOTAXIME INJECTION 1 g 375.00

<!-- page 3 -->

3I fldgi ( ^I& fPoh - YS% ,xld m%cd;dka;s%l iudcjd§ ckrcfha w;s úfYI .eiÜ m;%h - 2018'08'31
PART I : SEC. (I) - GAZETTE   EXTRA  ORDINARY   OF   THE   DEMOCRATIC   SOCIALIST   REPUBLIC   OF   SRI   LANKA - 31.08.2018
Column I Column II
Generic Name
Column III
Route of Administration/
dosage form
Column IV
Strength
Column V
MRP (SLR)
4 FLUCONAZOLE CAPSULE/TABLET 50 mg 25.00
FLUCONAZOLE CAPSULE/TABLET 150 mg 45.00
5 INSULIN SOLUBLE HUMAN INJECTION 100 IU/1ml
(10 ml vial)
1,200.00
INSULIN SOLUBLE HUMAN INJECTION 100 IU/1ml
(3 ml cartridge)
600.00
INSULIN ISOPHANE HUMAN INJECTION 100 IU/1ml
(10 ml vial)
1,200.00
INSULIN ISOPHANE HUMAN INJECTION 100 IU/1ml
(3 ml cartridge)
600.00
BIPHASIC ISOPHANE 
INSULIN (AS INSULIN 
SOLUBLE HUMAN 30IU/1ml, 
INSULIN ISOPHANE HUMAN 
70IU /1ml) 
INJECTION 100 IU/1ml
(10 ml vial)
1,200.00
BIPHASIC ISOPHANE
INSULIN (AS INSULIN
SOLUBLE HUMAN 30IU/1ml,
INSULIN ISOPHANE HUMAN
70IU /1ml)
INJECTION 100 IU/1ml
(3 ml cartridge)
600.00
6 GLIMEPIRIDE TABLET 1 mg 7.15
GLIMEPIRIDE TABLET 2 mg 10.15
GLIMEPIRIDE TABLET 3 mg 17.00
GLIMEPIRIDE TABLET 4 mg 18.50
7 SITAGLIPTIN TABLET 25 mg 15.00
SITAGLIPTIN TABLET 50 mg 28.50
SITAGLIPTIN TABLET 100 mg 48.50
8 TAMSULOSIN CAPSULE/TABLET 0.40 mg 21.00
9 MONTELUKAST TABLET 4 mg 12.00
MONTELUKAST TABLET 5 mg 15.00
MONTELUKAST TABLET 10 mg 21.00

<!-- page 4 -->

4 I fldgi ( ^I& fPoh - YS% ,xld m%cd;dka;s%l iudcjd§ ckrcfha w;s úfYI .eiÜ m;%h - 2018'08'31
PART I : SEC. (I) - GAZETTE   EXTRA  ORDINARY   OF   THE   DEMOCRATIC   SOCIALIST   REPUBLIC   OF   SRI   LANKA - 31.08.2018
Column I Column II
Generic Name
Column III
Route of Administration/
dosage form
Column IV
Strength
Column V
MRP (SLR)
10               PREGABALIN CAPSULE/TABLET 50 mg 12.25
              PREGABALIN CAPSULE/TABLET 75 mg 15.50
PREGABALIN CAPSULE/TABLET 100 mg 19.25
PREGABALIN CAPSULE/TABLET 150 mg 24.00
PREGABALIN CAPSULE/TABLET 300 mg 39.50
11 TOPIRAMATE CAPSULE/TABLET 25 mg 20.00
TOPIRAMATE CAPSULE/TABLET 50 mg 32.00
TOPIRAMATE CAPSULE/TABLET 100 mg 52.00
12 LAMOTRIGINE TABLET 25 mg 12.00
LAMOTRIGINE TABLET 50 mg 21.00
LAMOTRIGINE TABLET 100 mg 35.00
13 ATORV ASTATIN TABLET 5 mg 6.75
ATORV ASTATIN TABLET 40 mg 26.00
                                                                         
————————————————
L.D.-B 9/2016
NATIONAL MEDICINES REGULATORY AUTHORITY ACT, No. 5 OF 2015
REGULATIONS made by the Minister of Health, Nutrition and Indigenous Medicine under section 142 of the National 
Medicines Regulatory Authority Act, No.5 of 2015 read with sections 3 and 118 of the aforesaid Act. 
 Dr. RAJITHA SENARATNE,
 Minister of Health, Nutrition and Indigenous Medicine.
Colombo, 
29th August, 2018.
Regulations
1. These Regulations may be cited as the Medicines (Tender Pricing) Regulations of 2018.
2. There shall be a maximum price limit to determine the maximum tender prices (hereinafter referred to as the 
“MTP”) of the drugs speciﬁ ed in the Schedule hereto (hereinafter referred to as the “Scheduled drugs”).
09-322/1

<!-- page 5 -->

5I fldgi ( ^I& fPoh - YS% ,xld m%cd;dka;s%l iudcjd§ ckrcfha w;s úfYI .eiÜ m;%h - 2018'08'31
PART I : SEC. (I) - GAZETTE   EXTRA  ORDINARY   OF   THE   DEMOCRATIC   SOCIALIST   REPUBLIC   OF   SRI   LANKA - 31.08.2018
3. The MTP limits in respect of the scheduled drugs shall also be applicable to all brand names,  generic names, 
dosage forms and strengths of the Scheduled drugs.
4. No manufacturer, importer, trader, distributor, or any other person shall place bid for any procurement or quote 
for any other emergency purchase of any scheduled drugs as speci ﬁ ed in Column II of the Schedule, for a price above 
the maximum tender price as speci ﬁ ed in Column V thereof on and after the date on which these regulations come in to 
operation.
5. No governmental or semi-governmental institution shall accept any tender or make any emergency purchase of 
any scheduled drugs as speciﬁ ed in Column II of the Schedule, for a price above the maximum tender price as speci ﬁ ed in 
Column V thereof from the date on which these regulations come in to operation.
6. For the purpose of procurement or emergency purchase, where any dosage form or strength of the Scheduled 
drugs are not speciﬁ ed in such Schedule, the maximum price limit for such dosage forms or strengths shall be ﬁ xed by the 
National Medicines Regulatory Authority.
7. Notwithstanding the provisions of the preceding regulations, the maximum tender price of each such unit of the 
Scheduled drugs as speciﬁ ed in the Schedule shall be effective on and after the date of operation of these regulations until 
revised.  
8. Any person or institution who or which contravenes the provisions of these regulations commits an offence under 
the National Medicines Regulatory Authority Act, No.5 of 2015, and shall be triable under Part IV of the said Act.
SCHEDULE
MAXIMUM TENDER PRICES OF TEN SELECTED MEDICINE
Column I Column II
Generic Name
Column III
Route of Administration/ 
dosage form
Column IV
Strength
Column V
MTP 
(SLR)
1 TRASTUZUMAB INJECTION 150 mg 32,390.00
TRASTUZUMAB INJECTION 440 mg 95,000.00
2 BEV ACIZUMAB INJECTION 100 mg/4ml 35,000.00
3 RITUXIMAB INJECTION 100 mg/10 ml 11,000.00
RITUXIMAB INJECTION 500 mg/50 ml 55,000.00
4 MYCOPHENOLATE MOFETIL CAPSULE/TABLET 500 mg 15.00
5 PEGASPARAGINASE (PEGASPARGASE) INJECTION 3750 IU 140,000.00

<!-- page 6 -->

6 I fldgi ( ^I& fPoh - YS% ,xld m%cd;dka;s%l iudcjd§ ckrcfha w;s úfYI .eiÜ m;%h - 2018'08'31
PART I : SEC. (I) - GAZETTE   EXTRA  ORDINARY   OF   THE   DEMOCRATIC   SOCIALIST   REPUBLIC   OF   SRI   LANKA - 31.08.2018
L.D.B. 9/2016
THE NATIONAL MEDICINES REGULATORY AUTHORITY ACT, No. 5 OF 2015
REGULATIONS made by the Minister of Health, Nutrition and Indigenous Medicine under section 142 of the National 
Medicines Regulatory Authority Act, No. 5 of 2015 read with sections 3 and 118 of the aforesaid Act.
 Dr. RAJITHA SENARATNE,
 Minister of Health, Nutrition and Indigenous Medicine.
Colombo,   
29th August, 2018.
Regulations
1. These regulations may be cited as the Medical Devices (Pricing) Regulations, of 2018.
      
2. No manufacturer, importer, distributor, trader, provider, pharmacist, medical practitioner, a medical institution 
inclusive of a private medical institution or a person who is in possession of a medical device shall sell, offer for sale or 
charge for any medical device set out in the Schedule hereto, described by any brand name, approved name, models, sizes 
or pack sizes, above the Maximum Retail Price (MRP) stipulated therein. 
3. A manufacturer, importer, distributor, trader, provider, pharmacist, medical practitioner, a medical institution 
inclusive of a private medical institution or a person who is in possession of a medical device set out in the Schedule hereto, 
currently sells the said medical device at a price less than the maximum retail price set out in the Schedule hereto, is required 
to maintain the existing price without any price increase.   
 
Column I Column II
Generic Name
Column III
Route of Administration/ 
dosage form
Column IV
Strength
Column V
MTP 
(SLR)
6 PEMETREXED DISODIUM INJECTION 100 mg 3,120.00
PEMETREXED DISODIUM INJECTION 500 mg 15,600.00
7 BORTEZOMIB INJECTION 2 mg 14,500.00
8 PEGINTERFERON ALFA 2a INJECTION 180 mcg 27,700.00
9 ABIRATERONE ACETATE Tablet 250 mg 275.00
10 PEGFILGRASTIM INJECTION 6 mg/ 0.6 ml,
6 mg/1 ml
22,000.00
09-322/2
————————————————

<!-- page 7 -->

7I fldgi ( ^I& fPoh - YS% ,xld m%cd;dka;s%l iudcjd§ ckrcfha w;s úfYI .eiÜ m;%h - 2018'08'31
PART I : SEC. (I) - GAZETTE   EXTRA  ORDINARY   OF   THE   DEMOCRATIC   SOCIALIST   REPUBLIC   OF   SRI   LANKA - 31.08.2018
4. Every person or institution referred to in regulation 2, who sells or offer for sale or charges for any medical 
device which is described by its brand name, approved name, models, sizes or pack sizes set out in the Schedule hereto, 
shall issue a receipt clearly indicating the brand name or the approved name, pack size and the price of such medical device 
as a separate item.
5. The relevant Maximum Retail Price as set out in the Schedule, of each unit of item in the stock of such medical 
device manufactured or available for sale shall be printed or marked in their respective commercial package or label as 
expeditiously as practicable, prior to the expiry of a period of forty ﬁ ve days from the date of publication of these regulations.
6. Any manufacturer, importer, distributor, trader, provider, pharmacist, medical practitioner, a medical institution 
inclusive of private medical institution or a person who is in possession of such medical devices who contravenes the 
provisions of these regulations commits an offence and shall be triable under Part IV of the National Medicines Regulatory 
Authority Act, No. 5 of 2015.
7. It shall be the duty of every manufacturer, importer, distributor, trader, provider, pharmacist, medical practitioner, 
a medical institution inclusive of private medical institution and a person who is in possession of such medical devices to 
display at every retail outlet the Maximum Retail Price of the medical devices set out in the Schedule hereto.
8. Where the MRP of any brand name, model, size or pack size of such medical devices are not speci ﬁ ed in the 
Schedule, such MRP shall be ﬁ xed by the National Medicines Regulatory Authority.
9. In these regulations –
“Medical Practitioner” shall have the same meaning as in the Medical Ordinance (Chapter 105);
“Private Medical Institution” shall have the same meaning as in the Private Medical Institutions (Registration) 
Act, No. 21 of 2006.
SCHEDULE 
MAXIMUM RETAIL PRICES OF TWO SELECTED MEDICAL DEVICES
Column I Column II
Approved Name
Column III
MRP
(SLR)
1 BLOOD GLUCOSE MONITERING SYSTEM 2,750.00 Per Unit
2 TEST STRIPS
FOR BLOOD GLUCOSE MONITERING SYSTEM
50.00 Per Strip
09-322/3
                                                                                                                                                                                                                   
PRINTED  AT  THE  DEPARTMENT  OF  GOVERNMENT  PRINTING,  SRI  LANKA.